CA
DFTX

Crewe Advisors’s Definium Therapeutics DFTX Stock Holding History

Crewe Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.8K Hold
1,999
– – ﹤0.01% 402
2025
Q4 		$26.8K Hold
1,999
– – ﹤0.01% 437
2025
Q3 		$23.6K Hold
1,999
– – ﹤0.01% 467
2025
Q2 		$13K Hold
1,999
– – ﹤0.01% 427
2025
Q1 		$11.7K Hold
1,999
– – ﹤0.01% 414
2024
Q4 		$13.9K Hold
1,999
– – ﹤0.01% 397
2024
Q3 		$11.4K Hold
1,999
– – ﹤0.01% 473
2024
Q2 		$14.4K Hold
1,999
– – ﹤0.01% 613
2024
Q1 		$18.8K Hold
1,999
– – ﹤0.01% 505
2023
Q4 		$7.32K Hold
1,999
– – ﹤0.01% 232
2023
Q3 		$6.26K Hold
1,999
– – ﹤0.01% 277
2023
Q2 		$7.14K Hold
1,999
– – ﹤0.01% 436
2023
Q1 		$6.34K Hold
1,999
– – ﹤0.01% 610
2022
Q4 		$4.4K Hold
1,999
– – ﹤0.01% 698
2022
Q3 		$7K Hold
1,999
– – ﹤0.01% 768
2022
Q2 		$19K Buy
+1,999
New +$25.3K ﹤0.01% 435

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Crewe Advisors's DFTX Position: Q1 2026 in Review

Crewe Advisors held its Definium Therapeutics (DFTX) position steady in Q1 2026 at 1,999 shares worth $37.8K. The position accounts for ﹤0.01% of the portfolio, ranked #402.

Crewe Advisors first reported a position in DFTX in Q2 2022 and has held it in 16 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Crewe Advisors held 1,999 shares of Definium Therapeutics worth $37.8K as of Q1 2026.
  • Crewe Advisors left its Definium Therapeutics share count unchanged in Q1 2026.
  • Definium Therapeutics made up ﹤0.01% of Crewe Advisors's portfolio in Q1 2026, its #402 holding.
  • Crewe Advisors first reported a position in Definium Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Crewe Advisors's 13F filing for Q1 2026, filed 7 May 2026.